French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 per cent in a large final clinical trial.
Sanofi has invested more than 1.3 billion euros ($1.7 billion) in
French drugmaker Sanofi posted better-than-expected quarterly results, bolstered by strong emerging markets, breaking with a trend of earnings misses by European rivals AstraZeneca and GlaxoSmithkline.
Sanofi performed strongly in Chi
Novartis AG is slashing nearly 2,000 jobs in the US ahead of the patent loss of its top-selling blood pressure drug Diovan, the Swiss drugmaker said on Friday, just months after it said would scale back operations in Switzerland.